Tango Therapeutics Inc (TNGX)

$21.63 +0.41 (1.93%)
Market Cap 3.09B
Revenue (ttm) 62.38M
Net Income (ttm) -101.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -162.86%
Debt to Equity Ratio 0.00
Volume 2,924,600
Avg Vol 3,274,338
Day's Range N/A - N/A
Shares Out 142.69M
Stochastic %K 85%
Beta 1.31
Analysts Strong Sell
Price Target $21.40

Company Profile

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repress...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 320 4900
Address:
201 Brookline Avenue, Suite 901, Boston, United States
mohamettarik
mohamettarik Apr. 2 at 11:22 PM
$FSLY stock is trading at 6.8× revenus expectation of 2026... it is higher than fair price value with 60-130% of it fair price. higher new records despit all market was down have only one answer, shorts covering, means massive drop coming after short covers end !!! let see what next days say same apply to $TNGX
0 · Reply
mohamettarik
mohamettarik Apr. 2 at 4:29 PM
$FSLY $TNGX Fucking blowing my mind.... It is still happening
0 · Reply
Chauncy_Peppertooth
Chauncy_Peppertooth Apr. 2 at 4:05 PM
$TNGX i’m more impressed at how wrong you were a few months ago.
0 · Reply
mohamettarik
mohamettarik Apr. 2 at 3:13 PM
$TNGX Insider lost biggest opportunity ever... It is up again 😂😂 https://finance.yahoo.com/markets/stocks/articles/tango-therapeutics-insider-sells-304-175320292.html
0 · Reply
LabPsycho
LabPsycho Apr. 2 at 3:07 PM
$TNGX Just hit $22. People should be amazed at this prescient prediction below posted when this was about $16. Step 1. Completed
0 · Reply
mohamettarik
mohamettarik Apr. 2 at 2:30 PM
$TNGX Tango
0 · Reply
mohamettarik
mohamettarik Apr. 2 at 2:09 PM
$FSLY $TNGX both have similar way of trend up and down together per minute since a month ago... what is common between them ? they are different industries. also both move against market !!!
0 · Reply
mohamettarik
mohamettarik Mar. 30 at 12:06 PM
$TNGX they are making money !!! no science !!!
2 · Reply
biolover
biolover Mar. 27 at 6:57 PM
$VKTX something is not right. Same form came to $TNGX and also vanguard one of the biggest holders of $RVMD ( same form ). Three of top in all biotech. ( may be others too I didn’t look ). Either we are missing something or a mistake or he is out of all biotechs.
7 · Reply
FAF_314
FAF_314 Mar. 26 at 6:49 PM
$TNGX up 25% since this post...... OUCH!
0 · Reply
Latest News on TNGX
Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise

Mar 6, 2026, 4:02 PM EST - 4 weeks ago

Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise

Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 2:46 PM EST - 2 months ago

Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

Jan 8, 2026, 9:05 AM EST - 3 months ago

Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

Tango Therapeutics Appoints Sung Lee to Board of Directors

Jan 5, 2026, 7:00 AM EST - 3 months ago

Tango Therapeutics Appoints Sung Lee to Board of Directors

Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 7:00 AM EST - 3 months ago

Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference

Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 7:00 AM EST - 4 months ago

Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal Testing - Buy

Nov 21, 2025, 4:20 PM EST - 4 months ago

Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal Testing - Buy

Tango Therapeutics, Inc. (TNGX) Discusses Positive Clinical Data and Development Plans for Vopimetostat in MTAP-deleted Cancers Transcript

Oct 23, 2025, 5:07 PM EDT - 5 months ago

Tango Therapeutics, Inc. (TNGX) Discusses Positive Clinical Data and Development Plans for Vopimetostat in MTAP-deleted Cancers Transcript

Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement

Oct 23, 2025, 11:17 AM EDT - 5 months ago

Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement

Tango Therapeutics Announces $225 Million Financing

Oct 23, 2025, 7:20 AM EDT - 5 months ago

Tango Therapeutics Announces $225 Million Financing

Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025

Oct 6, 2025, 7:00 AM EDT - 6 months ago

Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025

Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

Aug 26, 2025, 7:00 AM EDT - 7 months ago

Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Aug 5, 2025, 7:00 AM EDT - 8 months ago

Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer

Jun 27, 2025, 7:00 AM EDT - 10 months ago

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer

Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

May 27, 2025, 7:00 AM EDT - 11 months ago

Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors

May 21, 2025, 7:00 AM EDT - 11 months ago

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 12, 2025, 7:00 AM EDT - 11 months ago

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

May 1, 2025, 7:00 AM EDT - 1 year ago

Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights

Feb 27, 2025, 7:00 AM EST - 1 year ago

Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights

Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference

Tango Therapeutics: Chance For A Short Squeeze

Jan 23, 2025, 5:44 AM EST - 1 year ago

Tango Therapeutics: Chance For A Short Squeeze

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 3, 2024, 7:00 AM EST - 1 year ago

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 27, 2024, 7:00 AM EST - 1 year ago

Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Nov 6, 2024, 7:05 AM EST - 1 year ago

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program

Nov 6, 2024, 7:00 AM EST - 1 year ago

Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program

Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data

Sep 10, 2024, 12:45 PM EDT - 1 year ago

Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data

Tango Therapeutics to Participate in Upcoming Investor Conferences

Aug 28, 2024, 7:00 AM EDT - 1 year ago

Tango Therapeutics to Participate in Upcoming Investor Conferences

Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

May 23, 2024, 9:18 AM EDT - 2 years ago

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

Tango Therapeutics to stop development of cancer therapy

May 23, 2024, 7:19 AM EDT - 2 years ago

Tango Therapeutics to stop development of cancer therapy

Tango Therapeutics Announces Discontinuation of TNG348 Program

May 23, 2024, 7:00 AM EDT - 2 years ago

Tango Therapeutics Announces Discontinuation of TNG348 Program

Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

May 8, 2024, 7:00 AM EDT - 2 years ago

Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights

Mar 18, 2024, 7:00 AM EDT - 2 years ago

Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024

Mar 5, 2024, 4:47 PM EST - 2 years ago

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024

Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Jan 31, 2024, 7:00 AM EST - 2 years ago

Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Tango Therapeutics: Making Its Way Into Clinic With 4 Innovative Cancer Drugs

Jan 25, 2024, 12:46 PM EST - 2 years ago

Tango Therapeutics: Making Its Way Into Clinic With 4 Innovative Cancer Drugs

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

Jan 4, 2024, 2:47 AM EST - 2 years ago

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting

Nov 13, 2023, 7:00 AM EST - 2 years ago

Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting

Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

Nov 8, 2023, 7:00 AM EST - 2 years ago

Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

Tango Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 7, 2023, 7:00 AM EST - 2 years ago

Tango Therapeutics to Present at the Jefferies London Healthcare Conference

Circling Bank On Tango Therapeutics

Oct 23, 2023, 6:26 PM EDT - 2 years ago

Circling Bank On Tango Therapeutics

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers

Tango Therapeutics Announces Updates to Its Board of Directors

Aug 29, 2023, 5:08 PM EDT - 2 years ago

Tango Therapeutics Announces Updates to Its Board of Directors

Tango Stock Surges On Peer Data Merits Excitement And Perspective

Aug 10, 2023, 7:30 AM EDT - 2 years ago

Tango Stock Surges On Peer Data Merits Excitement And Perspective

Tango Therapeutics Announces $80 million Private Placement Financing

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Tango Therapeutics Announces $80 million Private Placement Financing

Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights

Tango Therapeutics: Partial Phase 1 Data Has Not Helped

Jul 26, 2023, 7:29 PM EDT - 2 years ago

Tango Therapeutics: Partial Phase 1 Data Has Not Helped

Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers

Jul 24, 2023, 7:00 AM EDT - 2 years ago

Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers

mohamettarik
mohamettarik Apr. 2 at 11:22 PM
$FSLY stock is trading at 6.8× revenus expectation of 2026... it is higher than fair price value with 60-130% of it fair price. higher new records despit all market was down have only one answer, shorts covering, means massive drop coming after short covers end !!! let see what next days say same apply to $TNGX
0 · Reply
mohamettarik
mohamettarik Apr. 2 at 4:29 PM
$FSLY $TNGX Fucking blowing my mind.... It is still happening
0 · Reply
Chauncy_Peppertooth
Chauncy_Peppertooth Apr. 2 at 4:05 PM
$TNGX i’m more impressed at how wrong you were a few months ago.
0 · Reply
mohamettarik
mohamettarik Apr. 2 at 3:13 PM
$TNGX Insider lost biggest opportunity ever... It is up again 😂😂 https://finance.yahoo.com/markets/stocks/articles/tango-therapeutics-insider-sells-304-175320292.html
0 · Reply
LabPsycho
LabPsycho Apr. 2 at 3:07 PM
$TNGX Just hit $22. People should be amazed at this prescient prediction below posted when this was about $16. Step 1. Completed
0 · Reply
mohamettarik
mohamettarik Apr. 2 at 2:30 PM
$TNGX Tango
0 · Reply
mohamettarik
mohamettarik Apr. 2 at 2:09 PM
$FSLY $TNGX both have similar way of trend up and down together per minute since a month ago... what is common between them ? they are different industries. also both move against market !!!
0 · Reply
mohamettarik
mohamettarik Mar. 30 at 12:06 PM
$TNGX they are making money !!! no science !!!
2 · Reply
biolover
biolover Mar. 27 at 6:57 PM
$VKTX something is not right. Same form came to $TNGX and also vanguard one of the biggest holders of $RVMD ( same form ). Three of top in all biotech. ( may be others too I didn’t look ). Either we are missing something or a mistake or he is out of all biotechs.
7 · Reply
FAF_314
FAF_314 Mar. 26 at 6:49 PM
$TNGX up 25% since this post...... OUCH!
0 · Reply
SadyK189
SadyK189 Mar. 25 at 8:04 PM
Here is my Amazing daily "Stocktwits" report 2/2: $FEED $ROMA $TNGX $CV FEED Price 2.23. My post last night "Getting up on 4hours chart. Key support at 1.6 - 1.8. Next key level to test 2.65 - 2.85." It hit our desired zone and went till 2.88 today CV Price 8.15. My post was "Looking good on daily chart. Key support at 6.7 - 7.10. Next key level to test 8.8 - 9.2." It hit our desired zone and went till 9.17 today ROMA Price 5.37. My post last night "Still looking good on daily chart. Next key level to test is 8.9 - 9.35." It made a nice move to 11.60 today TNGX Initially alerted at 16.85. Then posted "Next key level to test is 21.10 - 21.70". It hit our desired zone and went till 21.80 today
1 · Reply
mohamettarik
mohamettarik Mar. 25 at 7:44 PM
$TNGX all time since IPO double top is confirmed,, time to roll back ,, all the way to $10 ... I am not advising to buy or sell ...
1 · Reply
SadyK189
SadyK189 Mar. 25 at 6:27 PM
$TNGX Initially alerted at 16.85. Mentioned 21.10 - 21.70 in following post. It hit our desired zone and at 21.32 right now
0 · Reply
Few_erish
Few_erish Mar. 25 at 4:40 PM
$TNGX this one woke up
0 · Reply
bobaboiz
bobaboiz Mar. 25 at 1:43 PM
$TNGX
1 · Reply
SadyK189
SadyK189 Mar. 23 at 12:13 AM
$TNGX Next key level to test is 21.10 - 21.70. Currently at 19.32
0 · Reply
JesusIsKing1
JesusIsKing1 Mar. 20 at 1:48 PM
$FSLY Starts red, finishes green. Every. Single. Day. Never known a stock like it, well maybe $TNGX and $TTE.
0 · Reply
LabPsycho
LabPsycho Mar. 19 at 8:01 PM
$TNGX Here is LabPsycho's Artificial Artificial Intelligence (A.^2 I. - Exponentially better than A.I. prediction (for amusement purposes only) on expected / potential near term events for TNGX: 1. Run up to close to $22/share 2. Offering around $18.75 raising maybe $250 million more.
0 · Reply
biolover
biolover Mar. 17 at 4:41 PM
$VKTX $TNGX story turned into how shorts can get out with big longs sticking in. Shorts realize it is a losing game with a clean drug that works. Big M&A target It is not about data anymore What is missing for now with VK is a CEO who can install confidence. I know for fact the drug is well tolerated in vanquish. Don’t want to comment on efficacy as don’t have solid numbers. Why can’t he emphasize that. ? People need to contact board to let Neil do all the talking. I even believe Neil is reading some of good Viking posts on media. I was impressed by a couple of points he recently highlighted. He should be the company spokesperson
2 · Reply
SadyK189
SadyK189 Mar. 16 at 8:07 PM
$TNGX mentioned 18.15 - 18.60 as next key level in following post. It hit our desired zone and went till 18.50 today
0 · Reply
bobaboiz
bobaboiz Mar. 16 at 3:06 PM
$TNGX next stop 20+
0 · Reply
biolover
biolover Mar. 12 at 6:15 PM
$TNGX nothing in the whole us market with stronger technicals than TNGX. Drug works. BIC. Partnership with $RVMD , tons of strong long instructions that joined from q2-q4 and massive SI that has to cover. The technical pressure up is even more intense than strong fundamentals.
0 · Reply